Home > Organization > Division of Cancer Immunotherapy (Kashiwa)
Group for Innovative Cancer TreatmentDivision of Cancer Immunotherapy (Kashiwa)
News
- Apr. 16, 2024
- Update Publication list
- Apr. 12, 2024
- Update Members
- May 1, 2023
- Update Publication list
- May 1, 2023
- Update Members
- Jul. 13, 2020
- We had a farewell ceremony for Toshiaki Yoshikawa
- Jul. 13, 2020
- Toshiaki Yoshikawa, belonged in our labo. for 13 years, has transferred to the Division of Immune Response, Aichi Cancer Center Research Institute as a Researcher. (He will continue to be a Visiting Researcher in our labo.)
- Jul. 1, 2020
- Update Members
- Jun. 11, 2020
- Update Publication list
- Jun. 11, 2020
- Update Members
- Jan. 16, 2020
- Update member list and Publication list.
- Jul. 18, 2019
- Our article, Cancer immunotherapy-targeted glypican-3 or neoantigens, published in Cancer Science, is one of the journal's top downloaded recent papers!Amongst articles published between January 2017 and December 2018, our paper received some of the most downloads in the 12 months following online publication.
- Jul. 17, 2019
- Update member list and Publication list.
Division of Cancer Immunotherapy (Kashiwa) has practiced from basic research to translational research through the development of cancer peptide vaccine therapy and has reported many research results. Currently, we integrate the knowledges and the latest technologies, and are working on the development of therapeutic and prophylactic methods with cancer vaccines, immune cell therapies including the use of induced pluripotent stem cell-derived immune cells, and their personalized applications. In addition, we are working on the development of diagnostic methods for recurrence and onset risk.
- Dr. T. Nakatsura, the Chief of this Division, and collaborators address the following four themes.
- Personalized cancer vaccine therapy
- Cancer antigen-specific T cell therapy
- Personalized T cell therapy
- Cancer Prevention Vaccine
Furthermore, we aim to establish a center for cell therapy in the future.
- Dr. Y. Uemura, the Leader of the Cell Therapy Unit, and collaborators have been developing immune cell preparation for cancer immunotherapy and generates a specific research area. Now they focus on the following three research projects:
- Regulation of tumor microenvironment
- Dendritic cell vaccine
- Immune effector cells
We are constantly devoted to research every days for developing effective cancer immunotherapy that many patients are looking forward to. We want to bring a smile for much more patients and their families. From now on, we will also focus on the development of personalized cancer immunotherapy and prevention methods. We hope that the time will come when human beings will overcome cancer by immunotherapy.
